| Literature DB >> 31815666 |
Fransky Hantelys1, Anne-Claire Godet1, Florian David1, Florence Tatin1, Edith Renaud-Gabardos1, Françoise Pujol1, Leila H Diallo1, Isabelle Ader2, Laetitia Ligat3, Anthony K Henras4, Yasufumi Sato5, Angelo Parini1, Eric Lacazette1, Barbara Garmy-Susini1, Anne-Catherine Prats1.
Abstract
Hypoxia, a major inducer of angiogenesis, triggers major changes in gene expression at the transcriptional level. Furthermore, under hypoxia, global protein synthesis is blocked while internal ribosome entry sites (IRES) allow specific mRNAs to be translated. Here, we report the transcriptome and translatome signatures of (lymph)angiogenic genes in hypoxic HL-1 mouse cardiomyocytes: most genes are induced at the translatome level, including all IRES-containing mRNAs. Our data reveal activation of (lymph)angiogenic factor mRNA IRESs in early hypoxia. We identify vasohibin1 (VASH1) as an IRES trans-acting factor (ITAF) that is able to bind RNA and to activate the FGF1 IRES in hypoxia, but which tends to inhibit several IRESs in normoxia. VASH1 depletion has a wide impact on the translatome of (lymph)angiogenesis genes, suggesting that this protein can regulate translation positively or negatively in early hypoxia. Translational control thus appears as a pivotal process triggering new vessel formation in ischemic heart.Entities:
Keywords: IRES; angiogenesis; cardiomyocyte; cell biology; chromosomes; gene expression; hypoxia; mouse; translational control; vasohibin
Mesh:
Substances:
Year: 2019 PMID: 31815666 PMCID: PMC6946400 DOI: 10.7554/eLife.50094
Source DB: PubMed Journal: Elife ISSN: 2050-084X Impact factor: 8.140